Fulgent Genetics, a publicly owned company headquartered in the United States, founded in 2011, reported $322.7M in revenue as of 2025. The company functions as a technology-based genetic testing provider, offering clinical diagnostic services, next-generation sequencing (NGS) panels, whole genome sequencing, carrier screening, prenatal testing, oncology profiling, and biopharma contract laboratory services. Its operations leverage proprietary technology platforms to deliver genomic insights for physicians, hospitals, and clinical research organizations.
Subscribe for full access to Fulgent Genetics's products in full detail 
